Oncology

CAR-T therapy
#CAR-T #European Commission #Janssen #Myeloma #Oncology #Phase III trial

EC expands use of BCMA-targeted CAR-T therapy

The European Commission (EC) has approved a Type II variation for Carvykti (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM). It is approved in patients who have received at least one prior therapy, including an immunomodulatory agent (IMiD)… Read More

#News #Regulatory

#Bioprinting #Cancer research #Cancer Research Horizons #Cancer Research UK #Cell therapy #Data #Data management #Data security #Drug development #Drug discovery #Electronic Lab Notebooks (ELN) #Laboratory data #Oncology #Organ manufacturing #Start-ups #Tissue engineering

Podcast looks behind the scenes of the drug discovery industry

This is the latest episode of the free DDW narrated podcast, titled “A look behind the scenes of the drug discovery industry” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Going paperless – the move to electronic lab… Read More

#News

Bowl of rice bran
#Japan #Nanomedicine / nanotechnology #Oncology #Precision medicine #Tokyo University of Science

Rice bran nanoparticles show promise as targeted cancer therapy

Researchers have discovered that nanoparticles derived from rice bran are both effective and safe for the treatment of cancer. Cancer therapies that employ nanoparticles can specifically target cancer cells, sparing healthy tissue. Recent studies have demonstrated that plant-derived nanoparticles (pdNPs) that have therapeutic effects… Read More

#Cancer Research #Editor's Choice #News

#Antibodies #Antiverse #Artificial intelligence (AI) #Generative AI #Oncology

Advancing antibody cancer therapeutics with AI

Antiverse is an artificial intelligence (AI)-driven company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Murat Tunaboylu, Co-founder and CEO of Antiverse, speaks with Megan Thomas about how AI can advance therapeutic antibody design. Megan T: How is Antiverse using… Read More

#Cancer Research #Exclusive Content

Multiple myeloma
#Blood cancer #Menarini #Myeloma #National Institute for Health and Care Excellence (NICE) #Oncology

Novel multiple myeloma drug recommended for UK NHS use

The UK’s National Institute for Health and Care Excellence (NICE) has published draft guidance recommending the use of Nexpovio (selinexor), in combination with bortezomib and dexamethasone, as a treatment for eligible multiple myeloma patients who have received one or two prior treatments. The recommendation follows recent… Read More

#News #Regulatory

Melanoma or skin cancer
#3D imaging #Cancer drug targets #Drug targets #Oncology #Skin cancer #The Institute of Cancer Research

Discovery reveals two potential drug targets against skin cancer

Scientists have discovered how skin cancer cells shapeshift based on their environment – enabling them to spread through the body and cause a metastatic cancer. The discovery of two genes responsible for sensing the environment and adapting cell shape could offer potential new drug targets to… Read More

#Cancer Research #Editor's Choice #News

CAR-T therapy
#Blood cancer #Leukaemia #National Institute for Health and Care Excellence (NICE) #Oncology #Paediatrics

UK’s NICE supports CAR-T for young people with leukaemia

The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Kymriah (tisagenlecleucel) for treating paediatric and young adults up to the age of 25 with B-cell acute lymphoblastic leukaemia (ALL). It is approved in cancers that are refractory, in relapse post-transplant or in second… Read More

#News #Regulatory

Prostate cancer cells
#mRNA #Nutcracker Therapeutics #Oncology #Prostate cancer #T cell activation

mRNA prostate cancer drug successfully engaged CD3 T cells

Nutcracker Therapeutics’ prostate cancer mRNA drug candidate NTX-470 successfully engaged CD3 T cells, while retaining low bystander activity and reduced off-tumour binding, according to data presented at the 2024 AACR Annual Meeting. There are limited treatment options for the 10-20% of prostate cancer patients who develop… Read More

#Cancer Research #News

#Antibodies #Cancer research #Oncology #Phase III trial #Therapeutic Antibodies

Improving the standard of care: Inside the DUO-E trial

Professor Shannon Westin is principal investigator of the DUO-E trial, here she speaks to DDW’s Megan Thomas about why the standard of care needs improving and the impact of therapeutic antibodies such as durvalumab. The DUO-E trial is a three-arm, randomised, double-blind, placebo-controlled, multicentre Phase III… Read More

#Cancer Research #Exclusive Content

#AACR #Cancer immunotherapy #Cancer research #Cancer therapeutics #Oncology

New DDW Highlights podcast: 15 April 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The cancer research news has been coming thick and fast from the American Association… Read More

#News

#AACR #Cancer immunotherapy #Cancer research #Cancer therapeutics #Oncology

This week in drug discovery (8-12 April) 

News round-up for 8-12 April by DDW Digital Content Editor Diana Spencer. The cancer research news has been coming thick and fast from the American Association of Cancer Research (AACR) Annual Meeting in San Diego this week, so our Friday round-up focuses on drug discovery in oncology. Read More

#News

Antibody drug conjugate
#Accelerated assessment #Antibody drug conjugate (ADC) #AstraZeneca #Daiichi Sankyo #FDA #Oncology #Solid tumours

First tumour agnostic HER2 directed ADC gets US approval

Daiichi Sankyo and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumours. Enhertu has been granted accelerated approval to treat patients who have received prior systemic treatment and… Read More

#News #Regulatory

Endometrial biopsy
#GSK #Oncology #Scottish Medicines Consortium (SMC) #Women's health

GSK’s endometrial cancer therapy approved in Scotland

The Scottish Medicines Consortium (SMC) has accepted GSK’s dostarlimab as a treatment for adult patients with endometrial cancer when used in combination with platinum-containing chemotherapy. Specifically, dostarlimab will be used for patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and… Read More

#News #Regulatory